GU Cancers 2025 | INTerpath-005: V940, an mRNA-based therapy, and pembrolizumab in MIBC
Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL, describes the Phase I/II INTerpath-005 trial (NCT06305767) of V940, an individualized mRNA-based neoantigen therapy, with pembrolizumab for muscle-invasive bladder cancer (MIBC). The study includes a perioperative cohort evaluating V940 with pembrolizumab and enfortumab vedotin before and after surgery, and an adjuvant cohort comparing V940 plus pembrolizumab versus pembrolizumab alone. Primary endpoints include safety and disease-free survival, with secondary analyses on pathologic response, overall survival, and distant metastasis-free survival. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
